Latest & greatest articles for statin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on statin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on statin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for statin

181. The Use of Statins for Antipsychotic Augmentation in Schizophrenia: Examination of Meta-Analyses With Flawed Methods and Conclusions. (Full text)

The Use of Statins for Antipsychotic Augmentation in Schizophrenia: Examination of Meta-Analyses With Flawed Methods and Conclusions. A very large number of psychopharmacologic agents have been trialed as antipsychotic augmentation strategies for the improvement of positive, negative, mood, cognitive, and other symptoms of schizophrenia; statins are one among these. Two very recent meta-analyses examined data on statin augmentation from 5 to 6 randomized controlled trials (RCTs) in the field (...) . One meta-analysis found that statins were superior to placebo for the improvement of total scale and general psychopathology subscale scores on the Positive and Negative Syndrome Scale; statins were no better than placebo for positive and negative subscale outcomes. The other meta-analysis, in contrast, found that statins were superior to placebo for the improvement of positive and negative subscale scores but were no better than placebo for total scale and general psychopathology subscale

2018 Journal of Clinical Psychiatry PubMed abstract

182. Do statins improve outcomes for patients with non-small cell lung cancer? A systematic review and meta-analysis protocol. (Full text)

Do statins improve outcomes for patients with non-small cell lung cancer? A systematic review and meta-analysis protocol. Lung cancer is the most common neoplasm and the leading cause of cancer-related death worldwide. Non-small cell lung cancer (NSCLC), accounting for 85% of all lung cancer cases, is frequently diagnosed at an advanced and metastatic stage. In addition, survival of patients with NSCLC has not improved significantly over the recent decades. Statins are used as a cholesterol (...) -lowering agent, but recently preclinical and clinical studies have revealed their anticancer effects. Thus, this systematic review and meta-analysis aims to clarify whether statins improve the prognosis of patients with NSCLC.We will search MEDLINE (PubMed), EMBASE, Web of Science, the Cochrane Central Register of Controlled Trials and ClinicalTrials.gov with no restriction on language. Both randomised controlled trials (RCTs) and observational cohort studies evaluating the prognostic role of statins

2018 BMJ open PubMed abstract

183. Statins for primary prevention of cardiovascular events and mortality in old and very old adults with and without type 2 diabetes: retrospective cohort study. (Full text)

Statins for primary prevention of cardiovascular events and mortality in old and very old adults with and without type 2 diabetes: retrospective cohort study. To assess whether statin treatment is associated with a reduction in atherosclerotic cardiovascular disease (CVD) and mortality in old and very old adults with and without diabetes.Retrospective cohort study.Database of the Catalan primary care system (SIDIAP), Spain, 2006-15.46 864 people aged 75 years or more without clinically (...) recognised atherosclerotic CVD. Participants were stratified by presence of type 2 diabetes mellitus and as statin non-users or new users.Incidences of atherosclerotic CVD and all cause mortality compared using Cox proportional hazards modelling, adjusted by the propensity score of statin treatment. The relation of age with the effect of statins was assessed using both a categorical approach, stratifying the analysis by old (75-84 years) and very old (≥85 years) age groups, and a continuous analysis

2018 BMJ PubMed abstract

184. Statin Use and Cancer Incidence in Patients with Type 2 Diabetes Mellitus: A Network Meta-Analysis (Full text)

Statin Use and Cancer Incidence in Patients with Type 2 Diabetes Mellitus: A Network Meta-Analysis Type 2 diabetes mellitus (T2DM) patients are involved closely with cancer. This work aims to conduct a systematic review and network meta-analysis (NMA) to examine the effect of different types of statins on cancer incidence in patients with T2DM.We systematically searched the Cochrane Library, PubMed, Embase, and Wanfang databases from January 1999 to March 2017. We performed a pairwise meta (...) 0.34 and 95% CI 0.12-0.93), fluvastatin (RR 0.27 and 95% CI 0.09-0.83), rosuvastatin (RR 0.22 and 95% CI 0.10-0.49), and pitavastatin (RR 0.33 and 95% CI 0.20-0.57) was superior to the nonstatin groups. When compared with six other statins, rosuvastatin appeared to be the best one.Different statins can reduce the risk of cancer in patients with T2DM. Our analyses suggest that rosuvastatin may be more effective than others.

2018 Gastroenterology research and practice PubMed abstract

185. Statins and the risk of intracerebral haemorrhage inpatients with stroke: systematic review and meta-analysis (Full text)

Statins and the risk of intracerebral haemorrhage inpatients with stroke: systematic review and meta-analysis Whether statins increase the risk of intracerebral haemorrhage (ICH) in patients with a previous stroke remains uncertain. This study addresses the evidence of statin therapy on ICH and other clinical outcomes in patients with previous ischaemic stroke (IS) or ICH.A systematic literature review and meta-analysis was performed in conformity with the Preferred Reporting Items (...) for Systematic Reviews and Meta-Analyses guidelines to assess observational and randomised studies comparing statin therapy with control (placebo or no treatment) in patients with a previous ICH or IS. The risk ratios (RR) for the primary outcome (ICH) and secondary outcomes (IS, any stroke, mortality and function) were pooled using random effects meta-analysis according to stroke subtype.Forty-three studies with a combined total of 317 291 patient-years of follow-up were included. In patients with previous

2018 EvidenceUpdates PubMed abstract

186. Meta-Analysis of Usefulness of Psyllium Fiber as Adjuvant Antilipid Therapy to Enhance Cholesterol Lowering Efficacy of Statins (Abstract)

Meta-Analysis of Usefulness of Psyllium Fiber as Adjuvant Antilipid Therapy to Enhance Cholesterol Lowering Efficacy of Statins Statins are usually well-tolerated drugs with a clear dose-dependent efficacy. However, manifestation of statin's side effects also bears a direct relation to higher doses necessary to achieve high impact cholesterol-lowering effects. Nevertheless, the reliance on statin efficacy alone has often left dietary intervention underutilized even though studies have shown (...) a reduction in serum cholesterol levels when dietary fiber intake is increased. In this meta-analysis, we investigated whether the concomitant use of psyllium, a gel-forming viscous soluble fiber, would cause further overall cholesterol lowering in subjects already receiving statins. A systematic review of the medical literature was performed and identified three randomized, controlled clinical studies that evaluated the cholesterol lowering efficacy of statins when given concomitantly with psyllium

2018 EvidenceUpdates

187. Statin

Statin Top results for statin - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for statin The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted

2018 Trip Latest and Greatest

188. Association of statin use with spontaneous intracerebral hemorrhage: A cohort study (Abstract)

Association of statin use with spontaneous intracerebral hemorrhage: A cohort study To examine the association between statin exposure in a dose-dependent manner and intracerebral hemorrhage (ICH) in a large nationwide study.The computerized database of the largest health care provider in Israel was used to identify diagnosed ICH among new users of statins, who started statin treatment between 2005 and 2010. We assessed a dose-response relationship between ICH and statins, using the average (...) and robust among highly persistent statin users and after controlling for the change in cholesterol level.This study confirms that the risk of ICH decreases with increasing cholesterol levels, but suggests that statin use might be associated with decreased risk of ICH.© 2018 American Academy of Neurology.

2018 EvidenceUpdates

189. The effects of statin therapy on mortality in patients with sepsis: A meta-analysis of randomized trials. (Full text)

The effects of statin therapy on mortality in patients with sepsis: A meta-analysis of randomized trials. Much controversy persists regarding the role of statins therapy in patients with sepsis. This systematic review and meta-analysis of randomized trials aimed to evaluate the clinical efficacy of statin therapy on mortality from sepsis.We comprehensively searched PubMed, Embase, and Cochrane controlled trials register for relevant clinical studies. Randomized controlled trials reporting (...) the effect of statin therapy on mortality in septic patients were included. Pooled risk estimates were calculated with a fixed-effects model. Heterogeneity was determined by Cochran chi-square test and the I statistic.Nine trials with a total of 2333 patients were included. Seven randomized trials were eligible for the in-hospital mortality analysis. There were 257 deaths among 1078 individuals in the statin treatment group and 268 deaths among 1081 individuals in the control group

2018 Medicine PubMed abstract

190. Statins on hepatocellular carcinoma risk in hepatitis B or C patients protocol for a systematic review and meta-analysis. (Full text)

Statins on hepatocellular carcinoma risk in hepatitis B or C patients protocol for a systematic review and meta-analysis. Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide. Chronic hepatitis B (HBV) and C virus (HCV) infection causes liver cancer. This protocol is to provide the methods used to assess the relationship between statins and HCC risk in hepatitis B or C patients.We will search comprehensively the PubMed (medline), Embase, Web of Science, Cochrane (...) Library, and China National Knowledge Infrastructure, Wanfang Database from their inception to November 2017. We will include studies that evaluated and clearly defined exposure to statins, reported the HCC incidence in hepatitis B/C patients or HBV/HCV-related cirrhosis patients, provided effective comparison groups, and reported risk estimates, such as hazard ratios, relative risks, or odds ratios with corresponding 95% confidence intervals or sufficient data for their estimation. We will use Stata

2018 Medicine PubMed abstract

191. Making Sense of the Statin-Prostate Cancer Relationship: Is It Time for a Randomized Controlled Trial? (Abstract)

and the University of Toronto, Toronto, Canada. Electronic address: rob.hamilton@uhn.ca. eng Editorial Comment 2016 06 23 Netherlands Eur Urol Focus 101665661 2405-4569 0 Hydroxymethylglutaryl-CoA Reductase Inhibitors EC 3.4.21.77 Prostate-Specific Antigen IM Eur Urol Focus. 2017 Apr;3(2-3):212-220 28753762 Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors Male Prostate-Specific Antigen Prostatic Neoplasms 2016 05 30 2016 06 13 2017 7 30 6 0 2018 7 11 6 0 2017 7 30 6 0 ppublish 28753767 S2405-4569(16)30068-2 (...) Making Sense of the Statin-Prostate Cancer Relationship: Is It Time for a Randomized Controlled Trial? 28753767 2018 07 10 2018 12 02 2405-4569 3 2-3 2017 04 European urology focus Eur Urol Focus Making Sense of the Statin-Prostate Cancer Relationship: Is It Time for a Randomized Controlled Trial? 221-222 S2405-4569(16)30068-2 10.1016/j.euf.2016.06.008 Hamilton Robert J RJ Division of Urology, Departments of Surgical Oncology, Princess Margaret Cancer Centre, University Health Network

2018 European urology focus Controlled trial quality: uncertain

192. Statin Pretreatment and Microembolic Signals in Large Artery Atherosclerosis: A Systematic Review and Meta-Analysis. (Full text)

Statin Pretreatment and Microembolic Signals in Large Artery Atherosclerosis: A Systematic Review and Meta-Analysis. Background and Purpose- Scarce data indicate that statin pretreatment (SP) in patients with acute cerebral ischemia because of large artery atherosclerosis may be related to lower risk of recurrent stroke because of a decreased incidence of microembolic signals (MES) during transcranial Doppler monitoring. Methods- We performed a systematic review and meta-analysis of available

2018 Stroke PubMed abstract

193. Statins in primary cardiovascular prevention. Little benefit, documented harms and many uncertainties regarding long-term use

Statins in primary cardiovascular prevention. Little benefit, documented harms and many uncertainties regarding long-term use Prescrire IN ENGLISH - Spotlight ''Statins in primary cardiovascular prevention. Little benefit, documented harms and many uncertainties regarding long-term use '', 1 July 2018 {1} {1} {1} | | > > > Statins in primary cardiovascular prevention. Little benefit, documented harms and many uncertainties regarding long-term use Spotlight Every month, the subjects (...) in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Statins in primary cardiovascular prevention. Little benefit, documented harms and many uncertainties regarding long-term use FEATURED REVIEW Given its weak efficacy and sometimes serious adverse effects, the harm-benefit balance of statin therapy in primary cardiovascular prevention is uncertain and close to neutral. Much else can be done to reduce

2018 Prescrire

194. Statins use and risk of dementia: A dose-response meta analysis. (Full text)

Statins use and risk of dementia: A dose-response meta analysis. Previous studies have indicated that statins use is associated with risk of dementia, but presented controversial results. Medline, Embase, Web of Science, and the Cochrane Database were searched update to November 2017 to identify the potential relationship between statins use and dementia. Thirty-one eligible studies involving a total of 3332,706 participants with 184,666 incident cases were included in this meta-analysis (...) . Statins use was associated with dementia risk decrement (relevant risk [RR]: 0.85; 95% confidence interval [CI], 0.80-0.89). Subgroup analysis showed statins use was associated with Alzheimer disease (AD) (RR: 0.81; 95% CI, 0.73-0.89) and non-AD dementia (RR: 0.81; 95% CI, 0.73-0.89) risk decrement. Furthermore, statins use was associated with dementia risk decrement in female (RR: 0.89; 95% CI, 0.80-0.98) and male (RR: 0.88; 95% CI, 0.83-0.93). In addition, a dose-response showed per 1 year

2018 Medicine PubMed abstract

195. Association of a Family History of Coronary Heart Disease With Initiation of Statin Therapy in Individuals at Intermediate Risk: Post Hoc Analysis of a Randomized Clinical Trial. (Full text)

Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota. Bailey Kent R KR Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota. Kullo Iftikhar J IJ Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota. eng Letter Pragmatic Clinical Trial Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't United States JAMA Cardiol 101676033 0 Hydroxymethylglutaryl-CoA Reductase Inhibitors IM Aged Coronary Disease drug (...) therapy genetics Female Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use Male Middle Aged 2016 7 21 6 0 2016 7 22 6 0 2018 6 27 6 0 ppublish 27438122 2513303 10.1001/jamacardio.2016.0227

2018 JAMA cardiology Controlled trial quality: uncertain PubMed abstract

196. Do statins prevent dementia?

Do statins prevent dementia? Do statins prevent dementia? – Morsels of Evidence \t\t\t\r\n\t\t\t \t\t\t\r\n\t\t\t Share this: Like this: Like Loading... ","author":{"@type":"Person","name":"Michael Tam"},"image":["https:\/\/evidencebasedmedicine.com.au\/wp-content\/uploads\/2018\/06\/mo-june2018-pp54-55.png"]} Toggle search form Toggle navigation Evidence-based medicine for general practitioners Jun 25 2018 Do statins prevent dementia? By in , , , , 25 June 2018 Journal reference: McGuinness B (...) , Craig D, Bullock R, Passmore P. Statins for the prevention of dementia. Cochrane database of systematic reviews 2016 Jan 4(1):CD003160 Link: Published: January 2016 Evidence cookie says… Statins should not be used as a prophylaxis against dementia, as the only indication the limited evidence from high quality randomised trials suggests no effect there is some ambiguity as observational data has tended to suggest a protective effect The article was published in the June 2018 issue of Medical Observer

2018 Morsels of Evidence

197. The annual rate of coronary artery calcification with combination therapy with a PCSK9 inhibitor and a statin is lower than that with statin monotherapy (Full text)

The annual rate of coronary artery calcification with combination therapy with a PCSK9 inhibitor and a statin is lower than that with statin monotherapy Statins and/or PCSK9 inhibitors cause the regression of coronary atheroma and reduce clinical events. However, it currently remains unclear whether these drugs modulate coronary atheroma calcification in vivo. Coronary artery calcium (CAC) scores (Agatston Units, AUs) were estimated in 120 patients receiving coronary computed tomographic (...) angiography (CCTA) (63% males; median age 56 years). The CAC scores were compared among the three groups: (1) neither statin nor PCSK9 inhibitor therapy, (2) statin monotherapy, and (3) statin and PCSK9 inhibitor combination therapy in an unpaired cross-sectional study. Additionally, CCTA was performed twice at an interval in 15 patients undergoing statin monotherapy to compare the previous (baseline) and subsequent (follow-up) CAC scores in a paired longitudinal study. In addition, a PCSK9 inhibitor

2018 NPJ aging and mechanisms of disease PubMed abstract

198. Reporting bias in the literature on the associations of health-related behaviors and statins with cardiovascular disease and all-cause mortality (Full text)

Reporting bias in the literature on the associations of health-related behaviors and statins with cardiovascular disease and all-cause mortality Reporting bias in the literature occurs when there is selective revealing or suppression of results, influenced by the direction of findings. We assessed the risk of reporting bias in the epidemiological literature on health-related behavior (tobacco, alcohol, diet, physical activity, and sedentary behavior) and cardiovascular disease mortality and all (...) -cause mortality and provided a comparative assessment of reporting bias between health-related behavior and statin (in primary prevention) meta-analyses. We searched Medline, Embase, Cochrane Methodology Register Database, and Web of Science for systematic reviews synthesizing the associations of health-related behavior and statins with cardiovascular disease mortality and all-cause mortality published between 2010 and 2016. Risk of bias in systematic reviews was assessed using the ROBIS tool

2018 PLoS biology PubMed abstract

199. Interactions between pro-inflammatory cytokines and statins on depression in patients with acute coronary syndrome. (Abstract)

Interactions between pro-inflammatory cytokines and statins on depression in patients with acute coronary syndrome. Pro-inflammatory cytokines are associated with the development of depression and statins exert anti-inflammatory and antidepressant effects. The present study aimed to investigate associations between interleukin (IL)-6 and IL-18 and depression in patients with acute coronary syndrome (ACS) and potential interactions between statin use and pro-inflammatory cytokines on depression (...) to statin use to determine whether any significant association emerged.Of the 969 participants, 378 (39.0%) had major or minor depression at baseline. Of 711 patients followed-up at 1year, 183 (25.7%) had depression. Logistic regression analysis showed that higher IL-6 and IL-18 levels at baseline were significantly associated with baseline depression after adjusting for other variables (adjusted p-values=0.005 and 0.001, respectively). IL-6 and IL-18 levels were also significantly higher in patients

2018 Progress in neuro-psychopharmacology & biological psychiatry

200. Statin use and all-cause mortality in people living with HIV: a systematic review and meta-analysis. (Full text)

Statin use and all-cause mortality in people living with HIV: a systematic review and meta-analysis. It is unknown whether statin use among people living with HIV results in a reduction in all-cause mortality. We aimed to evaluate the effect of statin use on all-cause mortality among people living with HIV.We conducted comprehensive literature searches of Medline, Embase, CINAHL, the Cochrane Library, and cross-references up to April 2018. We included randomised, quasi-randomised trials (...) and prospective cohort studies that examined the association between statin use and cardio-protective and mortality outcomes among people living with HIV. Two reviewers independently abstracted the data. Hazard ratios (HRs) were pooled using empirical Bayesian random-effect meta-analysis. A number of sensitivity analyses were conducted.We included seven studies with a total of 35,708 participants. The percentage of participants on statins across the studies ranged from 8 to 35%. Where reported, the percentage

2018 BMC Infectious Diseases PubMed abstract